The trial met prespecified non-inferiority criteria for its primary safety endpoint and primary efficacy endpoint. Outcomes were presented by Dr. Vinod Thourani (Piedmont Heart Institute, Atlanta, GA) during the opening Late-Breaking Clinical Trial sessions at the 2023 Transcatheter Cardiovascular Therapeutics (TCT) Annual Scientific Symposium in San Francisco, CA.<\/p>\n
ALIGN-AR Investigators concluded that Trilogy THV performance was excellent with large EOA and low transvalvular gradients, as well as low paravalvular regurgitation (0% \u2265 moderate at 1 year). In addition, echocardiography demonstrated significant improvement in LV remodeling, and patients reported sustained improvement in quality of life (QoL) and heart failure functional status through 1 year.<\/p>\n
\u201cWe are encouraged to see the significant LV mass reduction at over 20% and substantial improvement in quality of life in the ALIGN-AR pivotal trial results,\u201d said Torsten P. Vahl, MD, Principal Investigator of the ALIGN-AR trial. \u201cPending U.S. regulatory approval, we look forward to being able to offer the Trilogy THV System to our patients with ssAR.\u201d<\/p>\n
\u201cWe are incredibly pleased to share the ALIGN-AR results, which demonstrate safety and efficacy as well as exceptional technical performance and reversal of heart enlargement with the Trilogy THV system,\u201d said Dr. Duane Pinto, Chief Medical Officer at JenaValve. \u201cWe would especially like to thank the ALIGN-AR investigators and site participants for their tremendous work and impact for patients with aortic regurgitation.\u201d<\/p>\n
\u201cIn addition to its safety profile, the Trilogy THV system offered exceptional hemodynamic and technical performance in the ALIGN-AR trial,\u201d said Raj Makkar, MD, Cedars Sinai. \u201cI am excited that patients with ssAR may have the option to receive TAVR and its benefits in the future.\u201d<\/p>\n
The ALIGN-AR trial is a landmark prospective, single-arm investigation device exemption (IDE) study designed to assess the safety and efficacy of the Trilogy THV System in high-risk patients with symptomatic, severe AR. Results from the study are intended to support a Premarket Approval submission to the U.S. Food and Drug Administration (FDA). If approved, the Trilogy THV System would become the first and only transcatheter aortic valve replacement (TAVR) system in the U.S. indicated for the treatment of symptomatic, severe AR.<\/p>\n